2nd Annual Personalized Cancer Vaccine Summit

With industry eagerly anticipating readouts from Merck and Moderna’s Phase 3 trial of adjuvant V940 in combination with Keytruda, BioNTech, and Genentech’s global trials for BNT116 for non-small cell lung cancer, we are advancing ever closer to a commercially approved personalized cancer vaccine. Beyond mRNA, though, the field is expanding, as novel DNA, peptide, viral, and cellular vaccines accelerate towards the clinic and showcase improvements in efficacy and safety.

The 2nd Annual Personalized Cancer Vaccine Summit returns to Boston as the only strategic forum dedicated to platforming the full spectrum of individualized cancer vaccines. We are arming this community with the means to accelerate the development of their personalized immunotherapies for cancer patients in need.

With granular insights from early discovery and preclinical efforts through to the optimization of clinical and manufacturing strategies, it’s your one-stop shop to benchmark against competitors, challenges in efficacy, cost-effectiveness, and safety, and hear the latest clinical data poised to shape the field. Plus, in-depth discussions and data-driven case studies showcase the breadth of modalities in development, from RNA, Peptide, and DNA through to Viral and Cellular, enabling you to gain cross-modality learnings to improve your vaccine’s efficacy at the tumor level and ensure you select the right neoantigen type to set your vaccine up for success.

Join 80+ CXOs, VPs, and Directors of Oncology, Immunotherapy, and Vaccine R AND D from the field’s leading biopharma organizations to gain the insights and partners you require to translate your personalized vaccines into robust clinical candidates and commercially viable products for multiple tumor types.


URLs:
Website: https://go.evvnt.com/3246149-0?pid=2874
Brochure: https://go.evvnt.com/3246149-3?pid=2874

Category: Conferences | Science, Health & Medicine | Pharmaceuticals

Prices:
Conference + Focus Day (3 Day Pass) - Drug Developer Pricing: USD 4197.00,
Conference Only - Drug Developer Pricing: USD 2999.00,
Conference + Focus Day (3 Day Pass) - Academic Pricing: USD 3597.00,
Conference Only - Academic Pricing: USD 2599.00,
Conference + Focus Day (3 Day Pass)- Solution Provider Pricing: USD 5097.00,
Conference Only - Solution Provider Pricing: USD 3699.00

Speakers: Alan Rigby, Chief Executive Officer, Epitopea, Ananta Paine, Senior Associate, Guide Point Insights, Baochun Zhang, Assistant Professor - Medicine, Dana-Farber / Harvard Cancer Center, Diego Silva, Managing Director, Vaxine, Fernando Kreutz, Chief Executive Officer, Cellvax, Jean-francois Millau, Co-Founder and Chief Executive Officer, Tatum Bioscience, Jian Yan, Vice President - Research and Discovery, Geneos Therapeutics, Inc., Joann Peters, Chief Operating Officer, Geneos Therapeutics, Inc., Kristen Dahlgren, Chief Executive Officer and Founder, Cancer Vaccine Coalition, Lelia Delamarre, Director - Cancer Immunology Research and Distinguished Scientist, Genentech, Lisa Butterfield, Distinguished Scientist, Merck and Co, Maurizio Ceppi, Chief Scientific Officer, Transgene, Michelle Brown, Vice President, Moderna, Nick Valiante, Co-Founder and Chief Scientific Officer, Innovac Therapeutics, Ray Goodrich, Chief Scientific Officer/Vice President of R AND D, PhotonPharma, Robert Dillman, Chief Medical Officer, AiVita Biomedical, Roy de Souza, Co-Founder and Chief Executive Officer, BreakBio, Ruben Rizzi, Senior Vice President - Global Regulatory Affairs, BioNTech, Sean Sullivan, Vice President Technology Innovation and Development, Arcturus Therapeutics, Simone Steiner, Chief Technology Officer, Transgene, Stephen Schoenberger, Professor, La Jolla Institute for Immunology, Vassiliki Karantza, Associate Vice President - Clinical Research Oncology, Merck and Co, Vicki Norton, Chair of Life Science Division, Duane Morris LLP, Wolfgang Fischl, Chief Executive Officer, YGION Biomedical GmbH